Two Sigma Advisers LP Has $2.06 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Two Sigma Advisers LP reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 66.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 72,000 shares of the specialty pharmaceutical company's stock after selling 145,300 shares during the quarter. Two Sigma Advisers LP owned 0.22% of Collegium Pharmaceutical worth $2,063,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical during the fourth quarter worth about $40,000. KBC Group NV increased its holdings in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after buying an additional 982 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares during the period. Finally, FORA Capital LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $223,000.

Analyst Ratings Changes

A number of research analysts recently issued reports on COLL shares. Needham & Company LLC reissued a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus target price of $43.80.

Insiders Place Their Bets

In other news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock valued at $2,334,994 in the last 90 days. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL traded up $0.17 on Monday, hitting $29.31. The company had a trading volume of 247,918 shares, compared to its average volume of 421,877. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a market capitalization of $941.79 million, a price-to-earnings ratio of 12.63 and a beta of 0.63. The firm has a 50 day moving average of $28.00 and a two-hundred day moving average of $29.60.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same quarter last year, the company posted $1.45 earnings per share. The firm's quarterly revenue was up 22.7% on a year-over-year basis. On average, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.